Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel: This paper is also published in parallel in Archives of Medical Science [Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11(1): 1–23]

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial

(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550

ESC/EAS Guidelines for the management of dyslipidaemias

Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549

Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease

LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378

Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials

Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436

2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management

Authors Task Force Members, Kristensen, S. D., Knuuti, J., Saraste, A., Anker, S. D., Bøtker, H. E., Hert, S. D., Ford, I., González‐Juanatey, J. R., Görenek, B., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu282 · Cited by 1,698

Statin-associated myopathy

Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463

Statin-Associated Side Effects

Thompson, P. D., Panza, G. A., Zaleski, A. L., & Taylor, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 776

Safety and efficacy of statin therapy

Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424

Gender differences in the effects of cardiovascular drugs

Tamargo, J. L., Rosano, G. M. C., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K. P., Savarese, G., et al. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 325

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel

Cicero, A. F. G., Colletti, A., Bajraktari, G., Descamps, O. S., Djuric, D. M., Владиславович, Е. М., Fras, Z., Katsiki, N., Langlois, M. R., Latkovskis, G., et al. (2017) · Nutrition Reviews · doi:10.1093/nutrit/nux047 · Cited by 303

The Role of Nutraceuticals in Statin Intolerant Patients

Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272

Angiopoietin-like 3 in lipoprotein metabolism

Kersten, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.119 · Cited by 220

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components

Turner, R. M., & Pirmohamed, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010022 · Cited by 206

Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials

Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., Watts, G. F., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.008 · Cited by 195

Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications

Ruscica, M., Ferri, N., Banach, M., Sirtori, C. R., & Corsini, A. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac020 · Cited by 218

Lipid-modifying effects of nutraceuticals: An evidence-based approach

Sahebkar, A., Șerban, M.-C., Gluba-Brzózka, A., Mikhailidis, D. P., Cicero, A. F. G., Rysz, J., & Banach, M. (2016) · Nutrition · doi:10.1016/j.nut.2016.04.007 · Cited by 188

Management of Statin Intolerance in 2018: Still More Questions Than Answers

Toth, P. P., Patti, A. M., Giglio, R. V., Nikolić, D., Castellino, G., Rizzo, M., & Banach, M. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0259-7 · Cited by 193

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 168

Bergamot Reduces Plasma Lipids, Atherogenic Small Dense LDL, and Subclinical Atherosclerosis in Subjects with Moderate Hypercholesterolemia: A 6 Months Prospective Study

Toth, P. P., Patti, A. M., Nikolić, D., Giglio, R. V., Castellino, G., Biancucci, T., Geraci, F., David, S., Montalto, G., Rizvi, A. A., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00299 · Cited by 134

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions

Penson, P. E., Mancini, G. B. J., Toth, P. P., Martin, S. S., Watts, G. F., Sahebkar, A., Mikhailidis, D. P., Banach, M., & on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12344 · Cited by 110

Statins, Muscle Disease and Mitochondria

Ramachandran, R., & Wierzbicki, A. S. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6080075 · Cited by 91

Statins: Then and Now

Toth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 99

PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers

Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88

PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016

Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 87

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate

Hobbs, F. R., Banach, M., Mikhailidis, D. P., Malhotra, A., & Capewell, S. (2016) · BMC Medicine · doi:10.1186/s12916-016-0550-5 · Cited by 76

Topical mevastatin promotes wound healing by inhibiting the transcription factor c-Myc via the glucocorticoid receptor and the long non-coding RNA Gas5

Sawaya, A. P., Pastar, I., Stojadinović, O., Lazovic, S., Davis, S. C., Gil, J., Kirsner, R. S., & Tomic‐Canic, M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.811240 · Cited by 77

Molecular mechanisms of statin intolerance

Gluba-Brzózka, A., Franczyk, B., Toth, P. P., Rysz, J., & Banach, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59938 · Cited by 73

Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms

Bahrami, A., Bo, S., Jamialahmadi, T., & Sahebkar, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101024 · Cited by 68

Intensive LDL-cholesterol lowering therapy and neurocognitive function

Banach, M., Rizzo, M., Nikolić, D., Howard, G., Howard, V. J., & Mikhailidis (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.001 · Cited by 68

Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology

Janssen, L., Allard, N. A. E., Saris, C. G. J., Keijer, J., Hopman, M. T. E., & Timmers, S. (2019) · Physiological Reviews · doi:10.1152/physrev.00002.2019 · Cited by 71

Folic Acid Therapy Reduces the First Stroke Risk Associated With Hypercholesterolemia Among Hypertensive Patients

Qin, X., Li, J., Spence, J. D., Zhang, Y., Li, Y., Wang, X., Wang, B., Sun, N., Chen, F., Guo, J., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.014578 · Cited by 65

Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study

Nicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65

Lipids, blood pressure and kidney update 2015

Banach, M., Aronow, W. S., Șerban, M.-C., Rysz, J., Voroneanu, L. E., & Covic, A. C. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0169-0 · Cited by 57

Evaluating bempedoic acid for the treatment of hyperlipidaemia

Penson, P. E., McGowan, M. P., & Banach, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280458 · Cited by 52

Current Cardiovascular Risk Reports

(2013) · Current Cardiovascular Risk Reports · doi:10.1007/12170.1932-9563 · Cited by 52

Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice

Bosco, G., Di Giacomo Barbagallo, F., Spampinato, S., Lanzafame, L., Di Pino, A., Piro, S., Purrello, F., & Scicali, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062444 · Cited by 50

Expert opinion: the therapeutic challenges faced by statin intolerance

Patel, J., Martin, S. S., & Banach, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197202 · Cited by 51

The effect of bergamot on dyslipidemia

Giglio, R. V., Patti, A. M., Nikolić, D., Volti, G. L., Al‐Rasadi, K., Katsiki, N., Mikhailidis, D. P., Montalto, G., Ivanova, E. A., Orekhov, A. N., et al. (2015) · Phytomedicine · doi:10.1016/j.phymed.2015.12.005 · Cited by 49

Effect of Phoenix dactylifera seeds (dates) extract in triton WR-1339 and high fat diet induced hyperlipidaemia in rats: A comparison with simvastatin

Bouhlali, E. D. T., Hmidani, A., Bourkhis, B., Khouya, T., Harnafi, H., Filali-Zegzouti, Y., & Alem, C. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112961 · Cited by 49

Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland

Pająk, A., Szafraniec, K., Polak, M., Drygas, W., Piotrowski, W., Zdrojewski, T. R., & Jankowski, P. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59700 · Cited by 48

Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data

Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 48

Statins and muscle pain

Pergolizzi, J. V., Coluzzi, F., Colucci, R. D., Olsson, H., LeQuang, J. A., Al‐Saadi, J., & Magnusson, P. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1734451 · Cited by 47

Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go

Banach, M., & Penson, P. E. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25675 · Cited by 45

Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options

Șerban, M.-C., Banach, M., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1118055 · Cited by 43

Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential

Orekhov, A. N., & Ivanova, E. A. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.01.003 · Cited by 43

Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence

Camerino, G. M., Tarantino, N., Canfora, I., Bellis, M. D., Musumeci, O., & Pierno, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042070 · Cited by 47

Statin Intolerance

Banach, M., & Mikhailidis, D. P. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.004 · Cited by 42

Muscle and statins: from toxicity to the nocebo effect

Pedro‐Botet, J., Climent, E., & Benaiges, D. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1615053 · Cited by 40

Statin-associated muscle symptoms: position paper from the Luso-Latin American Consortium

Sposito, A. C., Faria‐Neto, J. R., de Carvalho, L. S. F., Lorenzatti, A. J., Cafferata, A., Elikir, G. D., Esteban, E., Villegas, E. C. M., Bodanese, L. C., Rodrigo Alonso, K., et al. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1252740 · Cited by 38

Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials.

Broncel, M., Gorzelak‐Pabiś, P., Sahebkar, A., Serejko-Banaś, K. E., Ursoniu, S., Rysz, J., Serban, M. C., Możdżan, M., & Banach, M. (2015) · PubMed Central · doi:10.5114/aoms.2015.54841 · Cited by 37

An evaluation of RVX-208 for the treatment of atherosclerosis

Nikolić, D., Rizzo, M., Mikhailidis, D. P., Wong, N. C. W., & Banach, M. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1083010 · Cited by 36

Multi-Centre Study on Cardiovascular Risk Management on Patients Undergoing AAA Surveillance

Saratzis, A. N., Dattani, N., Brown, A., Shalhoub, J., Bosanquet, D. C., Sidloff, D. A., & Stather, P. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.04.009 · Cited by 34

Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease

Paraskevas, K. I., Gloviczki, P., Antignani, P. L., Comerota, A. J., Dardik, A., Davies, A. H., Eckstein, H., Faggioli, G., Fernandes, J. F. E., Fraedrich, G., et al. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.05.003 · Cited by 35

Effects of 12-week supplementation of Citrus bergamia extracts-based formulation CitriCholess on cholesterol and body weight in older adults with dyslipidemia: a randomized, double-blind, placebo-controlled trial

Cai, Y., Xing, G., Tian, S., Zhang, S., Rao, J., & Shi, R. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0640-1 · Cited by 33

Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study

Camerino, G. M., Musumeci, O., Conte, E., Musaraj, K., Fonzino, A., Barca, E., Marino, M., Rodolico, C., Tricarico, D., Camerino, C., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00500 · Cited by 33

Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

Bandyopadhyay, D., Ashish, K., Hajra, A., Qureshi, A., & Ghosh, R. K. (2018) · Journal of Lipids · doi:10.1155/2018/3179201 · Cited by 32

The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment

Chojnacki, C. J., Błońska, A., & Chojnacki, J. (2017) · BioMed Research International · doi:10.1155/2017/3204504 · Cited by 30

A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key Processes Associated with Atherosclerosis In Vitro

Moss, J. W. E., Davies, T. S., Garaiová, I., Plummer, S. F., Michael, D. R., & Ramji, D. P. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151057 · Cited by 27

Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)

Katsiki, N., Mikhailidis, D. P., Bajraktari, G., Miserez, A. R., Cicero, A. F. G., Bruckert, É., Șerban, M.-C., Mirrakhimov, E. M., Alnouri, F., Reiner, Ž., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104719 · Cited by 27

HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015)

Oliveira, E. F., Santos‐Martins, D., Ribeiro, A. J. M., Brás, N. F., Cerqueira, N. M. F. S. A., Sousa, S. F., Ramos, M. J., & Fernandes, P. A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1216977 · Cited by 28

Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know

Paraskevas, K. I., Veith, F. J., Eckstein, H., Ricco, J., & Mikhailidis, D. P. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.176 · Cited by 25

Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel

Al-Ashwal, A. A., Alnouri, F., Sabbour, H. M., Almahfouz, A., Al-Sayed, N., Razzaghy‐Azar, M., Al-Allaf, F. A., Al-Waili, K., Banerjee, Y., Genest, J. J., et al. (2015) · Current Vascular Pharmacology · doi:10.2174/1570161113666150827125040 · Cited by 25

Recent Advances in Developing PCSK9 Inhibitors for lipid-lowering Therapy

Lavecchia, A., & Cerchia, C. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0294 · Cited by 26

Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study)

Mefford, M. T., Tajeu, G. S., Tanner, R. M., Colantonio, L. D., Monda, K. L., Dent, R. E., Farkouh, M. E., Rosenson, R. S., Safford, M. M., & Muntner, P. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.05.016 · Cited by 24

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

Banach, M., Lopez-Sendon, J. L., Averna, M. R., Cariou, B., Loy, M., Manvelian, G. Z., Batsu, I., Poulouin, Y., & Gaudet, D. (2021) · Archives of Medical Science · doi:10.5114/aoms/143476 · Cited by 24

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia

Pirillo, A., & Catapano, A. L. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000706 · Cited by 25

SAMSON and the Nocebo Effect: Management of Statin Intolerance

Krishnamurthy, A., Bradley, C., Ascunce, R. R., & Kim, S. M. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01729-x · Cited by 25

Thyroid hormones: a potential ally to LDL-cholesterol-lowering agents

Duntas, L. H., & Brenta, G. (2016) · HORMONES · doi:10.14310/horm.2002.1707 · Cited by 22

CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities

Walker, H. E., Rizzo, M., Fras, Z., Jug, B., Banach, M., & Penson, P. E. (2021) · Metabolites · doi:10.3390/metabo11120857 · Cited by 23

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

Penson, P. E., & Banach, M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00887-z · Cited by 23

Statin intolerance – a question of definition

Algharably, E. A. E., Filler, I., Rosenfeld, S., Grabowski, K., & Kreutz, R. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1238898 · Cited by 19

Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview

Katsiki, N., Stoian, A. P., Steiropoulos, P., Παπάνας, Ν., Suceveanu, A., & Mikhailidis, D. P. (2020) · Metabolites · doi:10.3390/metabo10110465 · Cited by 20

IMPROVE-IT

Banach, M., Nikolić, D., Rizzo, M., & Toth, P. P. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000305 · Cited by 19

Pharmacokinetic drug evaluation of ezetimibe + simvastatin for the treatment of hypercholesterolemia

Bove, M., Fogacci, F., & Cicero, A. F. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1381085 · Cited by 18

ESSENS dyslipidemia: A placebo-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia

Kasliwal, R. R., Bansal, M., Gupta, R., Shah, S., Dani, S., Oomman, A., Pai, V., Prasad, G. M., Singhvi, S., Patel, J., et al. (2016) · Nutrition · doi:10.1016/j.nut.2016.01.012 · Cited by 17

Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond

Wong, N. D., Rosenblit, P. D., & Greenfield, R. S. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.03.02 · Cited by 19

Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care

Wiggins, B. S., Backes, J. M., & Hilleman, D. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2681 · Cited by 17

LDL-Cholesterol-Lowering Therapy

Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17

Countering clinical inertia in lipid management: Expert workshop summary

Zullig, L. L., Egbuonu‐Davis, L., Trasy, A., Oshotse, C. O., Goldstein, K. M., & Bosworth, H. B. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.09.003 · Cited by 15

Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia

Muhindo, C. T., Ahn, S. A., Rousseau, M. F., Dierckxsens, Y., & Hermans, M. P. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.10.014 · Cited by 16

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up

Dixon, D. L., Buckley, L. F., Trankle, C. R., Kadariya, D., & Abbate, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114091 · Cited by 12

Dyslipidaemia in the elderly: to treat or not to treat?

Katsiki, N., Kolovou, G. D., Pérez‐Martínez, P., & Mikhailidis, D. P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1425138 · Cited by 14

Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study

Petrov, I. S., Dumitrescu, A., Šnejdrlová, M., Zafrir, B., Wożakowska−Kapłon, B., Fábryová, Ľ., Pintarić, H., Bridges, I. M., & Petkova, R. T. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0879-1 · Cited by 14

Bempedoic acid: new evidence and recommendations on use

Paponja, K., Pećin, I., Reiner, Ž., & Banach, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000911 · Cited by 13

Combination Therapy In Dyslipidemia

Banach, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8 · Cited by 12

Impact of educational outreach intervention on enhancing health care providers' knowledge about statin therapy prescribing in Malaysian patients with type 2 diabetes mellitus

Elnaem, M. H., Mohamed, M. H. N., Huri, H. Z., & Azarisman, S. M. (2018) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12903 · Cited by 12

Validation of a clinically-relevant rodent model of statin-associated muscle symptoms for use in pharmacological studies

Irwin, J. C., Fenning, A. S., Ryan, K., & Vella, R. K. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.040 · Cited by 12

The effect of Brassica vegetables on blood glucose levels and lipid profiles in adults. A systematic review and meta‐analysis

Darand, M., Alizadeh, S., & Mansourian, M. (2022) · Phytotherapy Research · doi:10.1002/ptr.7410 · Cited by 12

Thrombosis in vasculitis: An updated review of etiology, pathophysiology, and treatment

Zhu, K., Lv, F., Hou, X., Wang, F., Pang, L., & Zhong, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30615 · Cited by 11

Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease

Shek, A. B., Kurbanov, R. D., Abdullaeva, G. J., Nagay, A. V., Hoshimov, S. U., Nizamov, U. I., Васиковна, З. А., & Alieva, R. B. (2017) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2017.70597 · Cited by 11

Update of treatment of heart failure with reduction of left ventricular ejection fraction

Aronow, W. S. (2016) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2016.63002 · Cited by 11

Lipid-lowering Therapies in Myositis

Mizus, M. C., & Tiniakou, E. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00942-3 · Cited by 10

Evinacumab for the treatment of homozygous familial hypercholesterolemia

Gao, Y.-L., Zhang, B., & Yang, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2047934 · Cited by 10

Statin myopathy

Maghsoodi, N., & Wierzbicki, A. S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000282 · Cited by 10

Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

Shah, P. K., Glueck, C. J., Goldenberg, N., Min, S., Mahida, C., Schlam, I. M., Rothschild, M., Huda, A. N., & Wang, P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0416-7 · Cited by 9

Estimating Prevalence and Characteristics of Statin Intolerance among High and Very High Cardiovascular Risk Patients in Germany (2017 to 2020)

Parhofer, K. G., Anastassopoulou, A., Calver, H., Becker, C., Rathore, A., Dave, R., & Zamfir, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020705 · Cited by 9

The Burden of Statin Therapy based on ACC/AHA and NCEP ATP-III Guidelines: An Iranian Survey of Non-Communicable Diseases Risk Factors

Asgari, S., Abdi, H., Hezaveh, A. M., Moghisi, A., Etemad, K., Beni, H. R., & Khalili, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-23364-9 · Cited by 9

Causes of failure to achieve the low density lipoprotein cholesterol therapeutic target in patients with high and very high vascular risk controlled in Lipid and Vascular Risk Units. EROMOT study

Morales, C., Plana, N., Arnau, A., Matas, L., Mauri, M., Vila, À., Vila, L., Soler, C., Montesinos, J., Masana, L., et al. (2018) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2017.07.005 · Cited by 9

Statin protects men but not women with HIV against loss of muscle mass, strength, and physical function: a pilot study

Cárdenas, J. D. G., Oliveira, V. H. F., Borsari, A. L., Marinello, P. C., Longenecker, C. T., & Deminice, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-31643-3 · Cited by 8

Cholesterol Management in the Era of PCSK9 Inhibitors

Svatikova, A., & Kopecky, S. L. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0891-5 · Cited by 8

Machine Learning Applied to Cholesterol-Lowering Pharmacotherapy: Proof-of-Concept in High-Risk Patients Treated in Primary Care

Krentz, A. J., Haddon-Hill, G., Zou, X., Pankova, N., & Jaun, A. Y. R. (2023) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0009 · Cited by 8

Statin-associated side effects in patients attending a lipid clinic: evidence from a 6-year study

Barkas, F., Adamidis, P. S., Koutsogianni, A.-D., Liamis, G. L., & Liberopoulos, E. N. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.111313 · Cited by 7

ANMCO Position Paper: diagnostic–therapeutic pathway in patients with hypercholesterolaemia and statin intolerance

Gulizia, M. M., Colivicchi, F., Arca, M., Abrignani, M. G., Perna, G. P., Mureddu, G. F., Nardi, F., & Riccio, C. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux020 · Cited by 7

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

Choi, J., Khan, A. M., Jarmin, M., Goldenberg, N., Glueck, C. J., & Wang, P. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0493-7 · Cited by 7

Causas de no consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en pacientes de alto y muy alto riesgo vascular controlados en Unidades de Lípidos y Riesgo Vascular. Estudio EROMOT

Morales, C., Plana, N., Arnau, A., Matas, L., Mauri, M., Vila, À., Vila, L., Soler, C., Montesinos, J., Masana, L., et al. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2017.07.003 · Cited by 7

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al‐Rasadi, K., Aronow, W. S., Athyros, V. G., Djuric, D. M., Владиславович, Е. М., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 386

Statin intolerance – a question of definition

Algharably, E. A. E., Filler, I., Rosenfeld, S., Grabowski, K., & Kreutz, R. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1238898 · Cited by 19

Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects

Li, J., Liu, H.-H., Wu, N., Yeo, K. K., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Baek, S. H., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802426 · Cited by 19

2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance

Chien, S.-C., Chen, P.-S., Huang, Y., Tang, S., Li, Y.-H., & Yeh, H. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.11.017 · Cited by 26

P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel

Penson, P. E., Toth, P. P., Mikhailidis, D. P., Владиславович, Е. М., Fras, Z., Mitchenko, O., Pella, D., Sahebkar, A., Rysz, J., Reiner, Ž., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz747.0310 · Cited by 11